Alzheimer's Disease (AD) Cell Models for Research

Alzheimer's disease (AD) is the most common cause of dementia, affecting over 55 million people worldwide, with nearly 10 million new cases each year (WHO, 2023). The global burden is projected to triple by 2050, driven by aging populations. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and behavioral changes. It is the fifth leading cause of death among adults aged 65 and older in the United States (NIA). The economic cost is estimated at $1 trillion annually globally (WHO). Risk factors include age, genetics (APOE4), cardiovascular health, and lifestyle. There is no cure; current treatments only manage symptoms. The 5-year survival after diagnosis varies, but median survival is around 8-10 years from onset (NCI).

AD is ideal for mechanistic studies due to its well-defined pathology: extracellular amyloid-beta plaques and intracellular tau neurofibrillary tangles. However, the exact molecular mechanisms remain incompletely understood, and there is a high unmet need for disease-modifying therapies. Public datasets (e.g., ADNI, AMP-AD) provide extensive omics data. Gene-edited cell models allow precise manipulation of AD-associated genes (APP, PSEN1, PSEN2, APOE, TREM2) to dissect pathways and test therapeutic targets. Open questions include the role of neuroinflammation, synaptic dysfunction, and the interplay between amyloid and tau.

AD pathogenesis involves several interconnected pathways:

• • Amyloid hypothesis: Sequential cleavage of amyloid precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase (presenilin complex) generates amyloid-beta (Aβ) peptides. Imbalance in Aβ production/clearance leads to aggregation and plaque formation.
• • Tau hypothesis: Hyperphosphorylation of tau protein leads to detachment from microtubules, aggregation into neurofibrillary tangles, and synaptic toxicity.
• • Neuroinflammation: Microglial activation and astrocytosis contribute to neuronal damage. TREM2 and other innate immune genes modulate microglial response.
• • Mitochondrial dysfunction and oxidative stress: Impaired energy metabolism and increased reactive oxygen species (ROS) exacerbate neurodegeneration.
• • Cholinergic deficit: Loss of cholinergic neurons in the basal forebrain contributes to cognitive decline.

Data from ClinVar, COSMIC, and large GWAS studies.

Key signaling networks in AD:

• • MAPK/ERK pathway: Activated by oxidative stress and Aβ, leading to tau phosphorylation.
• • PI3K/AKT/mTOR pathway: Impaired insulin signaling contributes to neuronal survival deficits.
• • Wnt signaling: Dysregulation affects synaptic plasticity and neurogenesis.
• • NF-κB pathway: Mediates neuroinflammation.
• • Autophagy/lysosomal pathway: Impaired clearance of protein aggregates.
• • Synaptic signaling: Glutamatergic and GABAergic imbalances.

Organoids (3D brain organoids) derived from iPSCs recapitulate cell-cell interactions and can model AD pathology (e.g., amyloid plaques, tau tangles) more accurately than 2D cultures.

Common animal models for AD:

• • Transgenic mice: Overexpress mutant APP (e.g., Tg2576, APP/PS1) or tau (e.g., P301S).
• • Knock-in mice: Express humanized APP or PSEN1 mutations at endogenous levels (e.g., AppNL-G-F).
• • PDX (Patient-Derived Xenograft): Not typical for AD, but used for cancer; for AD, patient-derived iPSCs are used.
• • Induced models: Injection of Aβ or tau aggregates to induce pathology.
• • Zebrafish: Used for high-throughput screening.

CRISPR-Cas9 gene editing enables creation of isogenic cell lines with precise modifications in AD-related genes. Examples include:

• • APP knockout: Eliminates APP expression, reducing Aβ production.
• • PSEN1 knockout: Disrupts gamma-secretase activity.
• • APOE4 knock-in: Introduces the risk allele to study its effect on lipid metabolism and inflammation.
• • TREM2 knockout: Models microglial dysfunction.
• • Tau (MAPT) knockout: Reduces tau expression, studying its role in neurodegeneration.

These models are commercially available as sequence-verified, clonal cell lines, accelerating research by providing reproducible and validated tools. They are essential for target validation, drug screening, and mechanistic studies.

Gene-edited cell lines enable functional validation of genetic variants identified in GWAS. For example, knocking out TREM2 in microglial cell lines reveals its role in phagocytosis and inflammatory response. Similarly, APOE4 knock-in lines show altered cholesterol metabolism and increased Aβ aggregation. These models help prioritize therapeutic targets.

Isogenic pairs (e.g., wild-type vs. APP knockout) are used in high-throughput screens to identify compounds that specifically target amyloid pathway. Resistance mechanisms can be studied by exposing cells to drugs and selecting resistant clones, then identifying genetic changes via sequencing.

CRISPR screens with gene-edited cells can identify synthetic lethal interactions or genes that modulate Aβ or tau toxicity. For example, knocking out BACE1 in neuronal cells can reveal compensatory pathways. Such screens aid in discovering novel biomarkers and therapeutic targets.